BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded at $4.9 at last check on Monday, June 29, making an upward move of 1.66% on its previous day’s price.

Looking at the stock we see that its previous close was $4.83 and the beta (5Y monthly) reads 2.88 with the day’s price range being $4.8800 – 5.2850. In terms of its 52-week price range, BCRX has a high of $6.29 and a low of $1.38. The company’s stock has gained about 7.45% over that past 30 days.

There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the BCRX stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 9 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 3 have rated the BioCryst Pharmaceuticals, Inc. (BCRX) stock as a Hold, while 6 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the BCRX stock currently stands at 0, and the current price level is 12.96% off its SMA20 and 12.86% from its 50-day simple moving average. The RSI (14) is pointing at 60.08 while the volatility over the past week is 7.2% and jumps to 7.62% over the past one month. The beta value is 2.87, while the average true range (ATR) is currently pointing at 0.36. The average price target for the stock over the next 12 months is $8.57, with the estimates having a low of $4 and a high of $13. These price ends are -18.37% and +165.31% off the current price level respectively, although investors could be excited at the prospect of a +83.67% if the BCRX share price touches on the median price of $9.

Let’s briefly compare BioCryst (BCRX) stock to its peers. We find that today’s price change of +1.66% and +33.06% over the past 12 months for BCRX betters that of Zoetis Inc Cl A (ZTS), which has seen its stock price fall -0.01% in the latest trading session and is +17.65% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has dropped -1.42% today, and is +4.38% up over the past year, while Grifols S.A. (GRFS) is also up 1.66% yet its price remains in the green at 33.06% over the same period. Zoetis has a P/E ratio of 39.46 compared to BioCryst’s 0 and Takeda’s 22.6. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.81% and 1.11%, respectively, in early deals.

Coming back to BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), we note that the average 3-month trading volume was 10.83 Million, while that of the preceding 10-day period stands at 10.3 Million. Current shares outstanding are 176.4 Million.

According to data from Thomson Reuters, insiders hold 0.95% of the company’s shares while institutions hold 90.2%. The data shows that short shares as of June 14, 2020, stood at 20.63 Million at a short ratio of 2.63. This represents a 11.7% Short interest in Shares outstanding on June 14, 2020. Shares short rose in June from the previous month at 17.07 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +40% up in year-to-date price movement.